Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
103results about How to "Immune response" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
FcgammaRIIB-specific antibodies and methods of use thereof
ActiveUS20040185045A1Strong therapeutic activityEnhancing antibody-mediated effector functionSenses disorderAntipyreticTherapeutic antibodyTreatment effect
The present invention relates to antibodies or fragments thereof that specifically bind FcgammaRIIB, particularly human FcgammaRIIB, with greater affinity than said antibodies or fragments thereof bind FcgammaRIIA, particularly human FcgammaRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
Owner:MACROGENICS INC
Fcgamma-RIIB-specific antibodies and methods of use thereof
InactiveUS20050260213A1Good curative effectAvoid managementHybrid immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigen Binding FragmentTherapeutic effect
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
Owner:MACROGENICS INC
Fcgamma riib specific antibodies and methods of use thereof
InactiveUS20050215767A1Enhance immune responseImprove responseSenses disorderAntipyreticTherapeutic antibodyAntiendomysial antibodies
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
Owner:MACROGENICS INC
Anti-idiotypic antibody and its use in regulating the composition of T cell lymphocytes
The present invention provides an anti-idiotypic antibody having specific reactivity with an idiotope common to more than one type of anti-HIV-1 antibody, and having no specific reactivity with non-HIV-1 antibodies. The present invention provides methods of diagnosis, monitoring and treatment of HIV-related diseases through the use of this antibody or related compounds.
Owner:HEMA DIAGNOSTIC SYST
Humanized FcgammaRIIB-specific antibodies and methods of use thereof
ActiveUS7521542B2Immune responseAvoid immune responseSenses disorderNervous disorderFc(alpha) receptorTherapeutic antibody
The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.
Owner:MACROGENICS INC
FcgammaRIIB-specific antibodies and methods of use thereof
InactiveUS20060177439A1Good curative effectConvenient treatmentImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsCell activationImmune complex deposition
The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of FcγRIIB, particularly human FcγRIIB, and block the Fc binding site of human FcγRIIB. The invention provides methods of treating cancer and / or regulating immune complex mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.
Owner:MACROGENICS INC
Humanized Fc.gamma.RIIB-Specific Antibodies and Methods of Use Thereof
InactiveUS20080044417A1Good curative effectEnhanced effector functionDisease diagnosisTissue cultureFc(alpha) receptorFc receptor
The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.
Owner:MACROGENICS INC
FcgammaRIIB-specific antibodies and methods of use thereof
ActiveUS7425620B2Enhance immune responseImprove responseSenses disorderAntipyreticTherapeutic antibodyAntiendomysial antibodies
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
Owner:MACROGENICS INC
Methods for treating cold sores with anti-infective compositions
InactiveUS6211243B1Rapid decline of infectionFast decayAntibacterial agentsBiocideDiseaseAmmonium compounds
The present invention relates to a method of treated disordered epithelial tissues such as cold sores and other complications resulting from disorders such as herpes, and the like. The inventive method combines an anti-infective and / or antimicrobial active agent in a carrier, with vigorous agitation of the disordered epithelial tissue for topical treatment thereof under such conditions sufficient to achieve clinically discernable improvement of the disordered epithelial tissue. The preferred anti-infective and / or antimicrobial active agent is an organohalide such as a quaternary ammonium compound, preferably benzalkonium chloride. The inventive method may be used also in connection with a preferred applicator configuration.
Owner:CHURCH & DWIGHT CO INC
Anti-infective compositions for treating disordered tissue such as cold sores
The present invention relates to the treatment of disordered epithelial tissues such as cold sores and other complications resulting from disorders such as herpes, and the like. The invention relates to the use of an anti-infective and / or antimicrobial active agent in a carrier, with vigorous agitation of the disordered epithelial tissue for topical treatment thereof under such conditions sufficient to achieve clinically discernable improvement of the disordered epithelial tissue. The preferred anti-infective and / or antimicrobial active agent is an organohalide such as a quaternary ammonium compound, preferably benzalkonium chloride. The inventive method may be used also in connection with a preferred applicator configuration.
Owner:CHURCH & DWIGHT CO INC
FcγRIIB specific antibodies and methods of use thereof
ActiveUS8044180B2Enhance immune responseImprove responseAnimal cellsAntibody ingredientsTherapeutic antibodyTherapeutic effect
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
Owner:MACROGENICS INC
Humanized FcγRIIB-specific antibodies and methods of use thereof
InactiveUS7786270B2Immune responseAvoid immune responseDisease diagnosisTissue cultureFc(alpha) receptorCancer cell
The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.
Owner:MACROGENICS INC
FcGammaRIIB Specific Antibodies and Methods of Use Thereof
InactiveUS20090202537A1Balanced functionImmune responseSenses disorderNervous disorderFc(alpha) receptorImmunologic disorders
The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer (preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma), autoimmune disease, inflammatory disease or IgE-mediated allergic disorder. The present invention also encompasses the use of a humanized FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention with a vaccine composition.
Owner:MACROGENICS INC
Substance delivery via a rotating microabrading surface
ActiveUS7166086B2Increase gene expressionEnhance immune responseSurgical needlesMicroneedlesPhysical therapyDermatomal
A method and device for the delivery of a substance into skin via the rotational movement of a microabrader device reduces the effects of operator variability. The method includes applying a substance to an area of a patient's skin through the rotational movement of microprotrusions which may be imparted by a spring device present in the microabrader device or the motion of the operator through the handle of the microabrader device. The device may further include system and methods for monitoring pressure of the device against the skin and thereby promote consistency between applications and control of penetration depth. The delivered substance may be placed on the microprotrusions and a reconstituting liquid included in the microabrader device.
Owner:BECTON DICKINSON & CO
Method and device for the delivery of a substance including a covering
ActiveUS7316665B2Increase gene expressionEnhance immune responseSurgeryMicroneedlesBiomedical engineeringBioactive substance
Owner:BECTON DICKINSON & CO
Single chain recombinant t cell receptors
InactiveUS20060166875A1Improve stabilityUseful purposeCompound screeningApoptosis detectionDisulfide bondingExtracellular
A single chain T cell receptor (scTCR) comprising an a segment constituted by a TCR α chain variable region sequence fused to the N terminus of a TCR α chain constant region extracellular sequence, a β segment constituted by a TCR β chain variable region fused to the N terminus of a TCR β chain constant region extracellular sequence, and a linker sequence linking the C terminus of the a segment to the N terminus of the β segment, or vice versa, the constant region extracellular sequences of the α and β segments being linked by a disulfide bond, the length of the linker sequence and the position of the disulfide bond being such that the variable region sequences of the α and β segments are mutually orientated substantially as in native αβ T cell receptors. Complexes of two or more such scTCRs, and use of the scTCRs in therapy and in various screening applications are also disclosed.
Owner:IMMUNOCORE LTD +1
FcGammaRIIB Specific Antibodies and Methods of Use Thereof
InactiveUS20090017023A1Strong therapeutic activityEnhancing antibody-mediated effector functionHybrid immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsTherapeutic antibodyTreatment effect
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
Owner:MACROGENICS INC
Method and device for the delivery of a substance including a covering
ActiveUS20060047242A1Increase gene expressionEnhance immune responseSurgeryMicroneedlesBiomedical engineeringBioactive substance
Owner:BECTON DICKINSON & CO
FcGammaRIIB Specific Antibodies and Methods of Use Thereof
InactiveUS20090017026A1Strong therapeutic activityEnhancing antibody-mediated effector functionImmunoglobulins against animals/humansAntibody ingredientsTherapeutic antibodyTherapeutic effect
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
Owner:MACROGENICS INC
FcGammaRIIB Specific Antibodies and Methods of Use Thereof
ActiveUS20090092610A1Enhance immune responseImprove responseImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsCell activationImmune complex deposition
The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of FcγRIIB, particularly human FcγRIIB, and block the Fc binding site of human FcγRIIB. The invention provides methods of treating cancer and / or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.
Owner:MACROGENICS INC
FcGammaRIIB Specific Antibodies and Methods of Use Thereof
ActiveUS20090017027A1Strong therapeutic activityEnhancing antibody-mediated effector functionAnimal cellsImmunoglobulins against animals/humansTherapeutic antibodyTreatment effect
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
Owner:MACROGENICS INC
Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
ActiveUS20120027788A1Low cross-reactivityReduce adverse effectsFungiVirusesDiseaseSimian Adenoviruses
The present invention relates to novel adenovirus strains with an improved sero-prevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and / or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and / or the pharmaceutical composition for the therapy or prophylaxis of a disease.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions
The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v / v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.
Owner:BIOVIE INC +1
Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
ActiveUS20100297108A1Increase heightFavor selective antibody responseOrganic active ingredientsSenses disorderCell AggregationsSpecific immunity
A novel treatment of Alzheimer's disease and other disorders involving protein misfolding or aggregation is provided by enhancing or sustaining an antibody response against predominantly directed against pathological protein aggregates or neo-epitopes present on pathogenic forms of said protein or protein complex. Furthermore, therapeutic methods are also described, wherein ex vivo stimulated antigen-selected peripheral blood lymphocytes are regrafted into the cognate donor.
Owner:NEW YORK UNIV
Serotype of adenovirus and uses thereof
InactiveUS20050232900A1Avoid and diminish immune responseImmune responseBiocideGenetic material ingredientsCell bindingSerotype
Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described differ in at least capsid proteins (penton-base, hexon), proteins responsible for cell binding (fiber protein), and proteins involved in adenovirus replication. This difference in tropism and capsid protein among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins.
Owner:JANSSEN VACCINES & PREVENTION BV
Anti-infective compositions, methods and systems for treating disordered tissue
InactiveUS6759434B2Fast attackFast decayBiocideHydroxy compound active ingredientsDiseaseAmmonium compounds
The present invention relates to the treatment of disordered epithelial tissues such as cold sores and other complications resulting from disorders such as herpes, and the like. The invention relates to the use of an anti-infective and / or antimicrobial active agent in a carrier, with vigorous agitation of the disordered epithelial tissue for topical treatment thereof under such conditions sufficient to achieve clinically discernable improvement of the disordered epithelial tissue. The preferred anti-infective and / or antimicrobial active agent comprises an organohalide, such as a quaternary ammonium compound, preferably benzalkonium chloride. The inventive method may be used also in connection with a preferred applicator configuration.
Owner:CHURCH & DWIGHT CO INC
Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates
ActiveUS20100158952A1Prevent and reduce incidenceEnhance immune responseSenses disorderBacteriaMicroorganismTreatment field
Owner:TE BIOS
Suppression of a hypersensitivity immune response with unrelated antigen derived from allergen source material
InactiveUS20140010845A1Trigger immune responseReduce in quantitySenses disorderPeptide/protein ingredientsSource materialBystander Suppression
The present invention relates to the treatment of a hypersensitivity immune response, such as allergic rhinitis or asthma, via bystander suppression by use of an antigen unrelated to the allergen triggering the hypersensitivity immune response in an individual to be treated, wherein the antigen is obtainable from the source material comprising the “triggering” allergen.
Owner:ALK ABELLO SA
Signal-1/signal-2 bifunctional peptide inhibitors
InactiveUS20050107585A1Decreased LFA-1 : ICAM- signalingPreventing translocation stepCell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsMajor histocompatibilityPeptide sequence
A novel peptide sequence having the general formula AB wherein each of A and B represent a chain of amino acid residues and wherein said A chain is capable of binding with a major histocompatibility complex on an antigen presenting cell, and wherein said B chain is capable of binding with a Signal-2 receptor on an antigen presenting cell. Preferred forms of the peptide sequence further include an X chain positioned intermediate the A chain and the B chain. Moreover, preferred forms include an A chain which has at least about 10% sequence homology with a Signal-1 moiety, or is a peptidomimetic of a Signal-1 moiety, said B chain has at least 10% sequence homology with a Signal-2 receptor moiety, or is a peptidomimetic of a Signal-2 receptor moiety, and wherein the X chain has at least one amino acid residue, or is a peptidomimetic of that amino acid residue. Advantageously, the novel peptide sequence is capable of shifting a type-1 immune response to a type-2 immune response or from a type-2 immune response to a type-1 immune response.
Owner:KANSAS UNIV OF
Topical delivery of vaccines
InactiveUS20080009785A1Increase gene expressionEnhance immune responsePowder deliverySnake antigen ingredientsMedicinePeptide
The present invention provides improved methods for delivery of substances into the skin. It has been discovered that delivery of substances such as nucleic acids, amino acids, amino acid derivatives, peptides and polypeptides simultaneously with abrasion of the skin enhances delivery and the biological response as compared to application of the substance to previously abraded skin.
Owner:BECTON DICKINSON & CO
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com